Cognition Therapeutics (NASDAQ:CGTX) Posts Earnings Results, Misses Expectations By $0.01 EPS

Cognition Therapeutics (NASDAQ:CGTX) posted its quarterly earnings results on Thursday. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.01), Zacks reports. During the same period last year, the business posted ($0.27) EPS.

Cognition Therapeutics Price Performance

CGTX opened at $0.43 on Friday. The firm has a market capitalization of $17.73 million, a PE ratio of -0.44 and a beta of 1.03. Cognition Therapeutics has a fifty-two week low of $0.34 and a fifty-two week high of $2.95. The company’s 50-day moving average is $0.59 and its 200 day moving average is $0.55.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. Brookline Capital Management raised shares of Cognition Therapeutics to a “strong-buy” rating in a research note on Monday, January 27th. Chardan Capital lowered their price objective on Cognition Therapeutics from $11.00 to $8.00 and set a “buy” rating for the company in a research report on Friday. B. Riley upgraded Cognition Therapeutics from a “neutral” rating to a “buy” rating and upped their target price for the company from $1.00 to $1.50 in a report on Thursday, December 19th. Finally, HC Wainwright upped their price target on shares of Cognition Therapeutics from $5.00 to $6.00 and gave the company a “buy” rating in a research report on Thursday, December 19th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $7.70.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.